SynthesisJMIR medical informatics2025
Pharmacoepidemiologic Research Based on Common Data Models: Systematic Review and Bibliometric Analysis.
Synthesis in JMIR medical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Assessing Research Impact With Bibliometrics and Altmetrics: The Case of the Canadian Network for Observational Drug Effect Studies (CNODES).Pharmacoepidemiology and drug safety · 2026Article
- Pharmacoepidemiology unpacked: a roadmap for junior researchers.Frontiers in pharmacology · 2026Review
- Attitudes Toward Common Data Models Among Chinese Biomedical Professionals: Cross-Sectional Survey.JMIR medical informatics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The adoption of common data models (CDMs) has transformed pharmacoepidemiologic research by enabling standardized data formatting and shared analytical tools across institutions. These models facilitate large-scale, multicenter studies and support timely real-world evidence generation. However, no comprehensive global evaluation of CDM applications in pharmacoepidemiology has been conducted. Objective: This study aimed to conduct a systematic review and bibliometric analysis to map the landscape of CDM usage in pharmacoepidemiology, including publication trends, institutional authors and collaborations, and citation impacts. Methods: In total, 5 English databases (PubMed, Web of Science, Embase, Scopus, and Virtual Health Library) and 4 Chinese databases (CNKI, Wan-Fang Data, VIP, and SinoMed) were searched for studies applying CDMs in pharmacoepidemiology from database inception to January 2024. Two reviewers independently screened studies and extracted information about basic publication details, methodological details, and exposure and outcome information. The studies were categorized into 2 groups according to their Total Citations per Year (TCpY), and a comparative analysis was conducted to examine the differences in characteristics between the 2 groups. Results: A total of 308 studies published between 1997 and 2024 were included, involving 1580 authors across 32 countries and 140 journals. The United States led in both publication volume and citation counts, followed by South Korea. Among the 10 most cited studies, 7 used the Vaccine Safety Datalink, 2 used Sentinel, and one used Observational Medical Outcomes Partnership. Studies were stratified by TCpY to reduce citation bias from publication timing. Comparative analysis showed that high-TCpY studies were significantly more associated with multicenter collaboration (P=.008), United States-based institutions (P=.04), and vaccine-related research (P=.009). These studies commonly featured larger sample sizes, cross-regional data, and enhanced generalizability. International collaborations primarily occurred among North America, Europe, and East Asia, with limited involvement from limited-income countries. Conclusions: This study presents the first bibliometric overview of CDM-based pharmacoepidemiologic research. The consistent output from United States institutions and increasing engagement from South Korea underscore their central roles in this field. High-TCpY studies tend to be multicenter, collaborative, and vaccine-focused, reflecting structural factors linked to research visibility and influence. Stratified citation analysis supports the value of real-world data integration and international cooperation in producing impactful studies. The dominance of limited-income countries in collaboration networks highlights a need for broader inclusion of underrepresented regions. These findings can help researchers identify key contributors, guide partner selection, and target appropriate journals. As CDM-based methods continue to expand, fostering diverse and collaborative research efforts will be crucial for advancing pharmacoepidemiologic knowledge globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.